Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

other current assets 1,140,000 1,188,000

Total current assets 24,913,000 19,898,000

PROPERTY:

Leasehold improvements 669,000 646,000

Laboratory equipment 3,756,000 3,533,000

Furniture, fixtures and office equipment 913,000 873,000

5,338,000 5,052,000

Less accumulated depreciation and

amortization (3,537,000) (3,212,000)

Property, net 1,801,000 1,840,000

Other assets 1,527,000 1,259,000

TOTAL ASSETS $28,241,000 $22,997,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

JANUARY 31, APRIL 30,

2008 2007

Unaudited

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $2,387,000 $1,683,000

Accrued clinical trial site fees 244,000 228,000

Accrued legal and accounting fees 390,000 392,000

Accrued royalties and license fees 124,000 337,000

Accrued payroll and related costs 858,000 874,000

Notes payable, current portion - 379,000

Capital lease obligation, current portion 17,000 17,000

Deferred revenue 1,434,000 1,060,000

Other current liabilities 1,239,000 885,000

Total current liabilities 6,693,000 5,855,000

Notes pay
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research ... $4.4 million, compared to $8.0 million during the same period ... was $8.9 million, or $0.23 per basic and diluted share. ... period in 2014, of $8.7 million, or $0.27 per basic ... cash equivalents and investments totaled $117.5 million. , "During ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Biodata, ... notebook with integrated protocols and specimen management systems, ... solutions and consulting services for life science research, ... of Labguru’s newest feature: chemical structure and reaction ... features for biologists, bio-chemists, and more, the integration ...
(Date:4/30/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the ... R&D services provider, today announced that its board of ... April 29, 2015, from a consortium (the "Consortium") led ... chairman and chief executive officer of the Company, and ... transaction (the "Transaction") involving the acquisition of all outstanding ...
(Date:4/30/2015)... WA (PRWEB) April 30, 2015 ... developed ultrafiltration membranes, the PX, PY, and ... coupons, sheets, and disks. Designed to be ... these new membranes can fill critical process requirements ... hinder downstream processes. , “New regulations on industrial ...
Breaking Biology Technology:Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Sterlitech Offers New Ultrafiltration Membranes 2
... , , , For determining the optimal reagent for your cells , ... Contents , Kit Contents , Storage and Stability , ... Introduction , , , ... , , Effectene ...
... , QIAshredder spin columns are designed for simple and rapid homogenization , of cell ... , , Format: , ... , , Sample ... plant cell or tissue lysates, white blood cell lysates, , ...
... , , , Library siRNA is available against ... , Library siRNA is synthesised using patented TOM-Amidite chemistry, and , ... annealed, , desalted, and ready to use. A detailed certificate ... order. Library siRNAs are ready for transfection, , and are ...
Cached Biology Technology:Transfection Reagent Selector Kit Handbook 2Transfection Reagent Selector Kit Handbook 3Transfection Reagent Selector Kit Handbook 4Transfection Reagent Selector Kit Handbook 5Transfection Reagent Selector Kit Handbook 6Transfection Reagent Selector Kit Handbook 7Transfection Reagent Selector Kit Handbook 8Transfection Reagent Selector Kit Handbook 9Transfection Reagent Selector Kit Handbook 10Transfection Reagent Selector Kit Handbook 11Transfection Reagent Selector Kit Handbook 12Transfection Reagent Selector Kit Handbook 13Transfection Reagent Selector Kit Handbook 14Transfection Reagent Selector Kit Handbook 15Transfection Reagent Selector Kit Handbook 16Transfection Reagent Selector Kit Handbook 17Transfection Reagent Selector Kit Handbook 18Transfection Reagent Selector Kit Handbook 19Transfection Reagent Selector Kit Handbook 20Transfection Reagent Selector Kit Handbook 21Transfection Reagent Selector Kit Handbook 22Transfection Reagent Selector Kit Handbook 23Transfection Reagent Selector Kit Handbook 24Transfection Reagent Selector Kit Handbook 25Transfection Reagent Selector Kit Handbook 26Transfection Reagent Selector Kit Handbook 27Transfection Reagent Selector Kit Handbook 28Transfection Reagent Selector Kit Handbook 29Transfection Reagent Selector Kit Handbook 30QIAshredder Homogenizer 2
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... modern health research by providing a goldmine of stored human ... Can we make better use of these invaluable resources by ... the theme of an international conference being held in March ... and use of biobanks through harmonization? The ...
... of Public Health have for the first time identified ... multiple mosquito species capable of stopping the development of ... humans. By silencing the gene, caspar, the researchers ... parasite in Anopheles gambiae , A. stephensi ...
... Genomatix Software, a company with an outstanding track ... by high throughput technologies, announced today that it ... B1, "Identification and assignment of functionally corresponding regulatory ... the European Patent Office. The Patent relates ...
Cached Biology News:Harmonizing biobank research: An achievable world-wide goal 2Malaria immunity trigger found for multiple mosquito species 2Genomatix gets patent for comparative genomics method 2
... The 6820 GC system combines world-class ... Chemical QA/QC software, Agilents world-renowned support and ... consumables and supplies--a combination that lets you ... decisions based on dependable data. The Agilent ...
... The MSQ™ Plus is a ... on the market for both LC and ... triple orthogonal Atmospheric Pressure Ionization (API) source ... MSQ Plus is compatible with existing LC ...
... CHEMICON® CaspaTag™ Caspase-9 Pan-Caspase In Situ Assay ... detection of active caspases in cells undergoing ... only. Not for use in diagnostic or ... Detection Kits use a novel approach to ...
... Saccharomyces cerevisiae, as well as other yeasts, ... molecular biology laboratories. The ability to transform ... and linear DNAs using lithium based buffers ... transformations and library screening easy and reliable, ...
Biology Products: